Dimerix Says Mexican Composition of Matter Patent Granted for Drug Candidate

MT Newswires Live

Yesterday

Dimerix (ASX:DXB) said the Mexican Institute of Industrial Property (IMPI) granted a key composition of matter patent covering its drug candidate, DMX-652, according to a Monday Australian bourse filing.

The patent grant "N-cyanopyrrolidines with activity as USP30 inhibitors" was issued under patent number 438406 and provides composition of matter protection for DMX-652 until June 3, 2041.

The company's planned phase 2 study of DMX-652 in cardiac surgery-associated acute kidney injury will investigate the candidate's potential to prevent kidney injury and preserve renal function.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/news/2667368026"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667368026\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667368026?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667368026","market":"hk","top_or_hot":-1,"title":"Dimerix Says Mexican Composition of Matter Patent Granted for Drug Candidate","media":"MT Newswires Live","content":"<html><body><p> Dimerix (ASX:DXB) said the Mexican Institute of Industrial Property (IMPI) granted a key composition of matter patent covering its drug candidate, DMX-652, according to a Monday Australian bourse filing.</p><p>The patent grant \"N-cyanopyrrolidines with activity as USP30 inhibitors\" was issued under patent number 438406 and provides composition of matter protection for DMX-652 until June 3, 2041.</p><p>The company's planned phase 2 study of DMX-652 in cardiac surgery-associated acute kidney injury will investigate the candidate's potential to prevent kidney injury and preserve renal function.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dimerix Says Mexican Composition of Matter Patent Granted for Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDimerix Says Mexican Composition of Matter Patent Granted for Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-14 08:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dimerix (ASX:DXB) said the Mexican Institute of Industrial Property (IMPI) granted a key composition of matter patent covering its drug candidate, DMX-652, according to a Monday Australian bourse filing.</p><p>The patent grant \"N-cyanopyrrolidines with activity as USP30 inhibitors\" was issued under patent number 438406 and provides composition of matter protection for DMX-652 until June 3, 2041.</p><p>The company's planned phase 2 study of DMX-652 in cardiac surgery-associated acute kidney injury will investigate the candidate's potential to prevent kidney injury and preserve renal function.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2667368026","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667368026","pubTimestamp":1789344401,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dimerix  said the Mexican Institute of Industrial Property  granted a key composition of matter patent covering its drug candidate, DMX-652, according to a Monday Australian bourse filing.The patent grant \"N-cyanopyrrolidines with activity as USP30 inhibitors\" was issued under patent number 438406 and provides composition of matter protection for DMX-652 until June 3, 2041.The company's planned phase 2 study of DMX-652 in cardiac surgery-associated acute kidney injury will investigate the candidate's potential to prevent kidney injury and preserve renal function.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","USRD":"THEMES US R&D CHAMPIONS ETF","BK7508":"医药生物股","BK7501":"新冠治疗股","DMX":"DoubleLine Multi-Sector Income ETF","DXB.AU":"DIMERIX LTD"},"translate_title":"Dimerix 表示墨西哥物质组合物获得候选药物专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"USRD":0.69,"DXB.AU":1,"DMX":0.69},"content_text":"Dimerix (ASX:DXB) said the Mexican Institute of Industrial Property (IMPI) granted a key composition of matter patent covering its drug candidate, DMX-652, according to a Monday Australian bourse filing.The patent grant \"N-cyanopyrrolidines with activity as USP30 inhibitors\" was issued under patent number 438406 and provides composition of matter protection for DMX-652 until June 3, 2041.The company's planned phase 2 study of DMX-652 in cardiac surgery-associated acute kidney injury will investigate the candidate's potential to prevent kidney injury and preserve renal function.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}